NCT00633321 - Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation | Biotech Hunter

Enrollment

522

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

February 28, 2009

Conditions

Smoking

Interventions

BIOLOGICAL

TA-NIC

TA-NIC vaccine will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.

BIOLOGICAL

Placebo

Placebo will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.

Trial Locations (9)

CRI Worldwide, LLC Kirkbride Center, Philadelphia

Columbia Medical Practice, Columbia

Centennial Medical Group, Elkridge

Mayo Clinic, Rochester

Benchmark Research, Metairie

Benchmark Research - Fort Worth, Fort Worth

Benchmark Research, Austin

Benchmark Research, Sacramento

CNS Research Institute, P.C., Clementon